Invention Grant
- Patent Title: Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors
-
Application No.: US15309396Application Date: 2014-10-20
-
Publication No.: US10144737B2Publication Date: 2018-12-04
- Inventor: Minsheng Zhang , Yinfa Yan
- Applicant: ETERNITY BIOSCIENCE INC.
- Applicant Address: CN Lianyungang
- Assignee: JIANGSU HENGRUI MEDICINE CO., LTD.
- Current Assignee: JIANGSU HENGRUI MEDICINE CO., LTD.
- Current Assignee Address: CN Lianyungang
- Agency: Brinks Gilson & Lione
- Agent Yuezhong Feng
- International Application: PCT/US2014/061369 WO 20141020
- International Announcement: WO2015/178955 WO 20151126
- Main IPC: C07D487/04
- IPC: C07D487/04 ; C07D473/34
Abstract:
The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.
Public/Granted literature
- US20170114063A1 SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS Public/Granted day:2017-04-27
Information query
